J. Sparano, G. Hortobagyi, J. Gralow, E. Perez, and R. Comis, Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization, Breast Cancer Research and Treatment, vol.353, issue.Suppl 4, pp.511-527, 2010.
DOI : 10.1007/s10549-009-0433-y

P. Bedard, D. Leo, A. Piccart-gebhart, and M. , Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer, Nature Reviews Clinical Oncology, vol.24, issue.1, pp.22-36, 2010.
DOI : 10.1038/nrclinonc.2009.186

A. Buzdar, S. Singletary, V. Valero, D. Booser, N. Ibrahim et al., Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial, Clin Cancer Res, vol.8, pp.1073-1079, 2002.

I. Henderson, D. Berry, G. Demetri, C. Cirrincione, L. Goldstein et al., Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer, Journal of Clinical Oncology, vol.21, issue.6, pp.976-983, 2003.
DOI : 10.1200/JCO.2003.02.063

E. Mamounas, J. Bryant, B. Lembersky, L. Fehrenbacher, S. Sedlacek et al., Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results From NSABP B-28, Journal of Clinical Oncology, vol.23, issue.16, pp.3686-3696, 2005.
DOI : 10.1200/JCO.2005.10.517

M. Martin, T. Pienkowski, J. Mackey, M. Pawlicki, J. Guastalla et al., Adjuvant Docetaxel for Node-Positive Breast Cancer, New England Journal of Medicine, vol.352, issue.22, pp.2302-2313, 2005.
DOI : 10.1056/NEJMoa043681

H. Roche, P. Fumoleau, M. Spielmann, J. Canon, T. Delozier et al., Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial, Journal of Clinical Oncology, vol.24, issue.36, pp.5664-5671, 2006.
DOI : 10.1200/JCO.2006.07.3916

P. Ellis, P. Barrett-lee, L. Johnson, D. Cameron, A. Wardley et al., Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial, The Lancet, vol.373, issue.9676, pp.1681-1692, 2009.
DOI : 10.1016/S0140-6736(09)60740-6

H. Joensuu, P. Kellokumpu-lehtinen, P. Bono, T. Alanko, V. Kataja et al., Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer, New England Journal of Medicine, vol.354, issue.8, pp.809-820, 2006.
DOI : 10.1056/NEJMoa053028

M. Burnell, M. Levine, J. Chapman, V. Bramwell, K. Gelmon et al., Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer, Journal of Clinical Oncology, vol.28, issue.1, pp.77-82, 2009.
DOI : 10.1200/JCO.2009.22.1077

T. Evans, A. Yellowlees, E. Foster, H. Earl, D. Cameron et al., Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study, Journal of Clinical Oncology, vol.23, issue.13, pp.2988-2995, 2005.
DOI : 10.1200/JCO.2005.06.156

G. Fountzilas, D. Skarlos, U. Dafni, H. Gogas, E. Briasoulis et al., Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group, Annals of Oncology, vol.16, issue.11, pp.1762-1771, 2005.
DOI : 10.1093/annonc/mdi366

P. Francis, J. Crown, D. Leo, A. Buyse, M. Balil et al., Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial, JNCI Journal of the National Cancer Institute, vol.100, issue.2, pp.121-133, 2008.
DOI : 10.1093/jnci/djm287

URL : http://jnci.oxfordjournals.org/cgi/content/short/100/2/121

L. Gianni, J. Baselga, W. Eiermann, V. Porta, V. Semiglazov et al., Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer, Journal of Clinical Oncology, vol.27, issue.15, pp.2474-2481, 2009.
DOI : 10.1200/JCO.2008.19.2567

S. Jones, F. Holmes, O. Shaughnessy, J. Blum, J. Vukelja et al., Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735, Journal of Clinical Oncology, vol.27, issue.8, pp.1177-1183, 2009.
DOI : 10.1200/JCO.2008.18.4028

L. Goldstein, O. Neill, A. Sparano, J. Perez, E. Shulman et al., Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197, Journal of Clinical Oncology, vol.26, issue.25, pp.4092-4099, 2008.
DOI : 10.1200/JCO.2008.16.7841

M. Martin, A. Rodriguez-lescure, A. Ruiz, E. Alba, L. Calvo et al., Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer, JNCI Journal of the National Cancer Institute, vol.100, issue.11, pp.805-814, 2008.
DOI : 10.1093/jnci/djn151

A. Polyzos, N. Malamos, I. Boukovinas, A. Adamou, N. Ziras et al., FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG), Breast Cancer Research and Treatment, vol.353, issue.1, pp.95-104, 2010.
DOI : 10.1007/s10549-009-0468-0

URL : https://hal.archives-ouvertes.fr/hal-00535384

F. Cognetti, D. Laurentiis, M. , D. Matteis, A. Manzione et al., Sequential epirubicindocetaxel-CMF as adjuvant therapy for node-positive early breast cancer: updated results of the TAXIt216 randomized trial, Ann Oncol, vol.19, p.1820, 2008.

. Jacquemier, 13:R109 http://breast-cancer-research.com/content, Breast Cancer Research, vol.136, 2011.

D. Mastro, L. Costantini, M. Durando, A. Michelotti, A. Danese et al., Cyclophosphamide, epirubicin, and 5-fluorouracil versus epirubicin plus paclitaxel in node-positive early breast cancer patients: A randomized, phase III study of Gruppo Oncologico Nord Ovest-Mammella Intergruppo Group, Journal of Clinical Oncology, vol.26, issue.15_suppl, p.516, 2008.
DOI : 10.1200/jco.2008.26.15_suppl.516

U. Nitz, J. Huober, B. Lisboa, N. Harbeck, H. Fischer et al., Interim results of Intergroup EC-Doc Trial: A randomized multicenter phase III trial comparing adjuvant CEF/CMF to EC- docetaxel in patients with 1???3 positive lymph nodes, Journal of Clinical Oncology, vol.26, issue.15_suppl, p.515, 2008.
DOI : 10.1200/jco.2008.26.15_suppl.515

E. Bria, C. Nistico, F. Cuppone, P. Carlini, M. Ciccarese et al., Benefit of taxanes as adjuvant chemotherapy for early breast cancer, Cancer, vol.353, issue.suppl 1, pp.2337-2344, 2006.
DOI : 10.1002/cncr.21886

D. Laurentiis, M. Cancello, G. , D. Agostino, D. Giuliano et al., Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials, Journal of Clinical Oncology, vol.26, issue.1, pp.44-53, 2008.
DOI : 10.1200/JCO.2007.11.3787

T. Ferguson, N. Wilcken, R. Vagg, D. Ghersi, and A. Nowak, Taxanes for adjuvant treatment of early breast cancer, Cochrane Database Syst Rev, vol.266, issue.24, p.4421, 2007.
DOI : 10.1002/14651858.CD004421.pub2

M. Martin, A. Lluch, M. Segui, A. Ruiz, M. Ramos et al., Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen, Annals of Oncology, vol.17, issue.8, pp.1205-1212, 2006.
DOI : 10.1093/annonc/mdl135

F. Andre, K. Broglio, H. Roche, M. Martin, J. Mackey et al., Estrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis, Journal of Clinical Oncology, vol.26, issue.16, pp.2636-2643, 2008.
DOI : 10.1200/JCO.2007.14.9146

D. Hayes, A. Thor, L. Dressler, D. Weaver, S. Edgerton et al., HER2 and Response to Paclitaxel in Node-Positive Breast Cancer, New England Journal of Medicine, vol.357, issue.15, pp.1496-1506, 2007.
DOI : 10.1056/NEJMoa071167

J. Hugh, J. Hanson, M. Cheang, T. Nielsen, C. Perou et al., Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial, Journal of Clinical Oncology, vol.27, issue.8, pp.1168-1176, 2009.
DOI : 10.1200/JCO.2008.18.1024

F. Penault-llorca, F. Andre, C. Sagan, M. Lacroix-triki, Y. Denoux et al., Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor???Positive Breast Cancer, Journal of Clinical Oncology, vol.27, issue.17, pp.2809-2815, 2009.
DOI : 10.1200/JCO.2008.18.2808

M. Martin, A. Rodriguez-lescure, A. Ruiz, E. Alba, L. Calvo et al., Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer, Breast Cancer Research and Treatment, vol.27, issue.8, pp.149-157, 2010.
DOI : 10.1007/s10549-009-0663-z

URL : https://hal.archives-ouvertes.fr/hal-00535419

C. Dumontet, M. Krajewska, I. Treilleux, J. Mackey, M. Martin et al., BCIRG 001 Molecular Analysis: Prognostic Factors in Node-Positive Breast Cancer Patients Receiving Adjuvant Chemotherapy, Clinical Cancer Research, vol.16, issue.15, pp.3988-3997, 2010.
DOI : 10.1158/1078-0432.CCR-10-0079

J. Jacquemier, C. Ginestier, J. Rougemont, V. Bardou, E. Charafe-jauffret et al., Protein expression profiling identifies subclasses of breast cancer and predicts prognosis, Cancer Res, vol.65, pp.767-779, 2005.

T. Sorlie, C. Perou, R. Tibshirani, T. Aas, S. Geisler et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proceedings of the National Academy of Sciences, vol.98, issue.19, pp.10869-10874, 2001.
DOI : 10.1073/pnas.191367098

E. De-azambuja, F. Cardoso, G. De-castro, . Jr, M. Colozza et al., Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12???155 patients, British Journal of Cancer, vol.27, issue.10, pp.1504-1513, 2007.
DOI : 10.1002/1097-0142(19910115)67:2<421::AID-CNCR2820670217>3.0.CO;2-Q

R. Stuart-harris, C. Caldas, S. Pinder, and P. Pharoah, Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients, The Breast, vol.17, issue.4, pp.323-334, 2008.
DOI : 10.1016/j.breast.2008.02.002

J. Chang, A. Makris, M. Gutierrez, S. Hilsenbeck, J. Hackett et al., Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients, Breast Cancer Research and Treatment, vol.94, issue.11, pp.233-240, 2008.
DOI : 10.1007/s10549-007-9590-z

S. Darb-esfahani, S. Loibl, B. Muller, M. Roller, C. Denkert et al., Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy, Breast Cancer Research, vol.15, issue.5, p.69, 2009.
DOI : 10.2174/092986708783769759

L. Estevez, J. Cuevas, A. A. Florian, J. Lopez-vega, J. Velasco et al., Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study, Clin Cancer Res, vol.9, pp.686-692, 2003.

J. Sjostrom, C. Blomqvist, P. Heikkila, K. Boguslawski, A. Raisanen-sokolowski et al., Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer, Clin Cancer Res, vol.6, pp.3103-3110, 2000.

S. Paik, G. Tang, S. Shak, C. Kim, J. Baker et al., Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor???Positive Breast Cancer, Journal of Clinical Oncology, vol.24, issue.23, pp.3726-3734, 2006.
DOI : 10.1200/JCO.2005.04.7985

G. Viale, M. Regan, M. Mastropasqua, F. Maffini, E. Maiorano et al., Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer, JNCI Journal of the National Cancer Institute, vol.100, issue.3, pp.207-212, 2008.
DOI : 10.1093/jnci/djm289

J. Bartlett, A. Munro, J. Dunn, C. Mcconkey, S. Jordan et al., Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601), The Lancet Oncology, vol.11, issue.3, pp.266-274, 2010.
DOI : 10.1016/S1470-2045(10)70006-1

E. Mamounas, J. Bryant, B. Lembersky, L. Fehrenbacher, S. Sedlacek et al., Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results From NSABP B-28, Journal of Clinical Oncology, vol.23, issue.16, pp.3686-3696, 2005.
DOI : 10.1200/JCO.2005.10.517

D. Berry, C. Cirrincione, I. Henderson, M. Citron, D. Budman et al., Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer, JAMA, vol.295, issue.14, pp.1658-1667, 2006.
DOI : 10.1001/jama.295.14.1658

I. Kostopoulos, P. Arapantoni-dadioti, H. Gogas, S. Papadopoulos, V. Malamou-mitsi et al., Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose???dense sequential adjuvant chemotherapy, Breast Cancer Research and Treatment, vol.19, issue.3, pp.251-261, 2006.
DOI : 10.1038/sj.onc.1203685

D. Hayes, Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer?, The Breast, vol.18, pp.131-134, 2009.
DOI : 10.1016/S0960-9776(09)70287-5

F. Andre, C. Hatzis, K. Anderson, C. Sotiriou, C. Mazouni et al., Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor-Positive Breast Cancer, Clinical Cancer Research, vol.13, issue.7, pp.2061-2067, 2007.
DOI : 10.1158/1078-0432.CCR-06-2078

S. Noguchi, Predictive factors for response to docetaxel in human breast cancers, Cancer Science, vol.20, issue.9, pp.813-820, 2006.
DOI : 10.1002/cncr.20203

T. Aas, A. Borresen, S. Geisler, B. Smith-sorensen, H. Johnsen et al., Specific P53 mutations are associated with de Jacquemier et al. Breast Cancer Research http://breast-cancer-research.com/content/13/6/R109 novo resistance to doxorubicin in breast cancer patients, Nat Med, vol.13, issue.2, pp.109811-814, 1996.
DOI : 10.1038/nm0796-811

A. Wahl, K. Donaldson, C. Fairchild, F. Lee, S. Foster et al., Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis, Nature Medicine, vol.48, issue.1, pp.72-79, 1996.
DOI : 10.1038/nm0196-72

L. Pusztai, Gene expression profiling of breast cancer, Breast Cancer Research, vol.27, issue.S3, p.11, 2009.
DOI : 10.1200/JCO.2008.21.6887

A. Goldhirsch, W. Wood, A. Coates, R. Gelber, B. Thurlimann et al., Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011, Annals of Oncology, vol.22, issue.8, pp.1736-1747, 2011.
DOI : 10.1093/annonc/mdr304

M. Cheang, S. Chia, D. Voduc, D. Gao, S. Leung et al., Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer, JNCI Journal of the National Cancer Institute, vol.101, issue.10, pp.736-750, 2009.
DOI : 10.1093/jnci/djp082

A. Urruticoechea, I. Smith, and M. Dowsett, Proliferation Marker Ki-67 in Early Breast Cancer, Journal of Clinical Oncology, vol.23, issue.28, pp.7212-7220, 2005.
DOI : 10.1200/JCO.2005.07.501

G. Viale, A. Giobbie-hurder, M. Regan, A. Coates, M. Mastropasqua et al., Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole, Journal of Clinical Oncology, vol.26, issue.34, pp.5569-5575, 2008.
DOI : 10.1200/JCO.2008.17.0829

R. Yerushalmi, R. Woods, P. Ravdin, M. Hayes, and K. Gelmon, Ki67 in breast cancer: prognostic and predictive potential, The Lancet Oncology, vol.11, issue.2, pp.174-183, 2010.
DOI : 10.1016/S1470-2045(09)70262-1

M. Bonetti and R. Gelber, A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data, Statistics in Medicine, vol.10, issue.19, pp.2595-2609, 2000.
DOI : 10.1002/1097-0258(20001015)19:19<2595::AID-SIM562>3.0.CO;2-M

. Jacquemier, 1186/bcr3051 Cite this article as Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC -PACS 01 randomized trial, Breast Cancer Research, vol.13, pp.10-109, 2011.